Compare Stocks: AMGN, SNY, and CRSP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$377.35 -1.3%	$400.37	$269.77 ▼ $447.03	$206.78B	0.43	2.46 million shs	2.27 million shs
CRSP CRISPR Therapeutics	$51.72 -1.0%	$53.49	$44.12 ▼ $78.48	$5.05B	1.76	1.42 million shs	855,572 shs
SNY Sanofi	$42.77 +0.1%	$43.95	$40.89 ▼ $52.68	$103.57B	0.35	2.02 million shs	2.37 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.34%	-13.70%	-9.33%	+6.24%	+35.49%
CRSP CRISPR Therapeutics	-1.03%	-7.30%	-4.20%	+3.86%	-0.17%
SNY Sanofi	+0.12%	-3.32%	-2.15%	-3.34%	-9.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$377.35 -1.3%	$400.37	$269.77 ▼ $447.03	$206.78B	0.43	2.46 million shs	2.27 million shs
CRSP CRISPR Therapeutics	$51.72 -1.0%	$53.49	$44.12 ▼ $78.48	$5.05B	1.76	1.42 million shs	855,572 shs
SNY Sanofi	$42.77 +0.1%	$43.95	$40.89 ▼ $52.68	$103.57B	0.35	2.02 million shs	2.37 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.34%	-13.70%	-9.33%	+6.24%	+35.49%
CRSP CRISPR Therapeutics	-1.03%	-7.30%	-4.20%	+3.86%	-0.17%
SNY Sanofi	+0.12%	-3.32%	-2.15%	-3.34%	-9.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$381.68	1.15% Upside
CRSP CRISPR Therapeutics	2.61	Moderate Buy	$68.06	31.58% Upside
SNY Sanofi	2.38	Hold	$49.50	15.74% Upside

Current Analyst Ratings Breakdown

Latest AMGN, SNY, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	SNY Sanofi	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	AMGN Amgen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$445.00 ➝ $425.00
9/8/2026	SNY Sanofi	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform
9/8/2026	AMGN Amgen	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$450.00
9/8/2026	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$400.00
9/4/2026	AMGN Amgen	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$400.00 ➝ $435.00
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/31/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$82.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	5.55	$33.36 per share	11.31	$16.08 per share	23.47
CRSP CRISPR Therapeutics	$3.51M	1,424.73	N/A	N/A	$20.17 per share	2.56
SNY Sanofi	$48.92B	2.12	$7.07 per share	6.05	$33.27 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$16.09	23.45	15.45	2.76	22.95%	124.14%	13.18%	11/3/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	22.39	8.09	1.29	8.66%	14.19%	7.95%	10/30/2026 (Estimated)

Latest AMGN, SNY, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	AMGN Amgen	$5.62	$6.29	+$0.67	$4.37	$9.43 billion	$10.05 billion
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.67%	+8.27%	62.65%	14 Years
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.76	4.12%	+6.46%	92.15%	N/A

Latest AMGN, SNY, and CRSP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	AMGN Amgen	quarterly	$2.52	2.29%	8/21/2026	8/21/2026	9/11/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	4.44	1.37	1.13
CRSP CRISPR Therapeutics	0.34	17.85	17.85
SNY Sanofi	0.21	0.99	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
CRSP CRISPR Therapeutics	69.20%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
CRSP CRISPR Therapeutics	5.20%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	540.63 million	536.04 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

AMGN, SNY, and CRSP Headlines

Recent News About These Companies

Sanofi Partners With USA Pickleball On COVID-19 Protection Campaign

September 10 at 12:15 PM | rttnews.com

Archford Capital Strategies LLC Invests $1.42 Million in Sanofi $SNY

September 10 at 3:21 AM | marketbeat.com

Astra, Roche win new outperform ratings as RBC initiates EU pharma coverage

September 9 at 1:52 PM | msn.com

Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Hold" from Brokerages

September 2, 2026 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen

August 29, 2026 | marketbeat.com

SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?

August 28, 2026 | zacks.com

Sanofi (NASDAQ:SNY) Receives Average Rating of "Hold" from Analysts

August 28, 2026 | marketbeat.com

US FDA approves updated COVID vaccines for 2026-27 season

August 27, 2026 | reuters.com

Sanofi stock steadies after strong Q2 2026 and upgraded guidance

August 21, 2026 | ad-hoc-news.deA

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | insidermonkey.com

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | finance.yahoo.com

Sanofi 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Sanofi Says EU Expands MenQuadfi Approval

August 5, 2026 | finance.yahoo.com

Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease

August 5, 2026 | msn.com

Why Investors Should Look at L3Harris, Cenovus, and Sanofi

August 5, 2026 | baystreet.ca

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | manilatimes.netM

Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | globenewswire.com

Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...

August 1, 2026 | sg.finance.yahoo.com

Sanofi says weak decision-making hurt pipeline, promises more disciplined R&D

July 30, 2026 | msn.com

Press Release: Sanofi’s half-year financial report for 2026

July 30, 2026 | markets.businessinsider.com

Sanofi Q2 Business Earnings, Sales Rise; Raises 2026 Sales Guidance

July 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMGN, SNY, and CRSP Company Descriptions

Amgen NASDAQ:AMGN

$377.35 -5.12 (-1.34%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$377.82 +0.47 (+0.13%)

As of 09/11/2026 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CRISPR Therapeutics NASDAQ:CRSP

$51.72 -0.54 (-1.03%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$51.76 +0.05 (+0.09%)

As of 09/11/2026 07:47 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Sanofi NASDAQ:SNY

$42.77 +0.05 (+0.12%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$42.72 -0.05 (-0.13%)

As of 09/11/2026 07:56 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMGN, SNY, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMGN, SNY, and CRSP Earnings

Compare Dividends

Latest AMGN, SNY, and CRSP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMGN, SNY, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMGN, SNY, and CRSP Company Descriptions

Amgen NASDAQ:AMGN

CRISPR Therapeutics NASDAQ:CRSP

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMGN, SNY, and CRSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMGN, SNY, and CRSP Earnings

Compare Dividends

Latest AMGN, SNY, and CRSP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMGN, SNY, and CRSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMGN, SNY, and CRSP Company Descriptions

Amgen NASDAQ:AMGN

CRISPR Therapeutics NASDAQ:CRSP

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools